ProQR Therapeutics (NASDAQ:PRQR) Receives $9.50 Average Target Price from Analysts

ProQR Therapeutics (NASDAQ:PRQR) has been given an average rating of “Buy” by the six ratings firms that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $9.50.

PRQR has been the subject of several recent research reports. JMP Securities reiterated a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Oppenheimer assumed coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 target price for the company. Citigroup upgraded ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Monday, March 10th. Chardan Capital reaffirmed a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th. Finally, HC Wainwright raised their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, March 14th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. M&T Bank Corp acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $330,000. BNP Paribas Financial Markets boosted its position in ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC boosted its position in ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares in the last quarter. Ballentine Partners LLC bought a new stake in shares of ProQR Therapeutics during the fourth quarter worth $61,000. Finally, Platinum Investment Management Ltd. acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth $4,076,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Price Performance

NASDAQ PRQR opened at $1.65 on Friday. The firm has a 50-day moving average price of $2.14 and a two-hundred day moving average price of $2.61. ProQR Therapeutics has a 12-month low of $1.59 and a 12-month high of $4.62. The company has a market capitalization of $173.60 million, a P/E ratio of -5.16 and a beta of 0.24.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).